Abstract
Calciphylaxis occurs rarely in the absence of end stage renal disease. Predisposing factors for nonuremic calciphylaxis (NUC) include hyperparathyroidism, coagulopathies, connective tissue disease, liver disease, glucocorticoid use, and malignancy. Warfarin can facilitate vascular calcification by reducing vitamin K-dependent carboxylation of matrix-Gla proteins. An 86-year-old Caucasian woman with a history of polymyalgia rheumatica, two spontaneous deep venous thromboses (DVTs) and multiple fractures was treated with calcium, vitamin D, prednisone, and warfarin. The patient's low bone density was treated initially with estrogen, then oral bisphosphonate, which was discontinued due to upper gastrointestinal symptoms. Nasal calcitonin was initiated. After 10 years of calcitonin treatment, she was changed to teriparatide. Two months after initiating teriparatide, she developed lower extremity edema and painful erythematous nodular lesions on her calves bilaterally, that progressed to necrotic ulcers despite antibiotic therapy. Biopsy of the lesions showed calcification in the media of small blood vessels and subcutaneous fat with fat necrosis, consistent with calciphylaxis. Teriparatide was discontinued. Aggressive wound care, antibiotics, and intravenous zoledronic acid were initiated. With cessation of teriparatide therapy and intensive wound care, the patient's lesions resolved over 8 months. We report the first case of NUC precipitated by teriparatide therapy. Our patient had multiple underlying predisposing factors including a connective tissue disorder, glucocorticoid therapy, warfarin use, and possible underlying coagulopathy given her history of multiple DVTs. In such patients, alternative osteoporosis therapies may be preferred.
References
Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143
Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20
Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090
Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982
Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471
Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579
Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157
Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260
Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054
Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344
Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767
Howe AM, Webster WS (2000) Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 81:51–56
Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81
Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260
Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217
Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389
Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962
Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142
Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was partially supported by the NIH T32 training grant (#101776).
Rights and permissions
About this article
Cite this article
Spanakis, E.K., Sellmeyer, D.E. Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment. Osteoporos Int 25, 1411–1414 (2014). https://doi.org/10.1007/s00198-013-2580-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-013-2580-6